Keywords: actelion, well-placed, success, endothelin, antagonists, heart, swiss
Actelion well-placed for success with endothelin antagonists for heart
Article | 21 September 2000
Swiss biopharmaceutical company Actelion has burst into the imaginationof investors in 2000, with a number of brokers initiating coverage of the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
